Achieve Life Retained Earnings Over Time
| ACHV Stock | USD 4.49 0.01 0.22% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Achieve Life Performance and Achieve Life Correlation. Achieve |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achieve Life. If investors know Achieve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achieve Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Return On Assets (0.54) | Return On Equity (1.86) |
The market value of Achieve Life Sciences is measured differently than its book value, which is the value of Achieve that is recorded on the company's balance sheet. Investors also form their own opinion of Achieve Life's value that differs from its market value or its book value, called intrinsic value, which is Achieve Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achieve Life's market value can be influenced by many factors that don't directly affect Achieve Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achieve Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Achieve Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achieve Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Analysis
Compare Achieve Life Sciences and related stocks such as VectivBio Holding, Icosavax, and Apellis Pharmaceuticals Retained Earnings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLS | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (24.6 M) | (71.1 M) | (98.3 M) | (149.3 M) | (276.8 M) | (581.5 M) | (926.3 M) | (1.7 B) | (2.3 B) | (2.8 B) | (2.7 B) |
| ITOS | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (35.9 M) | (73.9 M) | 140.6 M | 237.3 M | 124.6 M | 70 M |
| TCRX | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (43.5 M) | (92.2 M) | (158.4 M) | (247.6 M) | (235.2 M) |
| DAWN | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (56.8 M) | (127.5 M) | (269.7 M) | (458.6 M) | (435.7 M) |
| ABOS | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (27 M) | (127.6 M) | (170.4 M) | (222.8 M) | (211.7 M) |
| XFOR | (35.4 M) | (35.4 M) | (35.4 M) | (35.4 M) | (35.4 M) | (35.4 M) | (58.4 M) | (92.3 M) | (135.3 M) | (132 M) | (194.2 M) | (282.9 M) | (376.7 M) | (477.9 M) | (454 M) |
| INZY | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (34.7 M) | (91.1 M) | (147.7 M) | (214.8 M) | (285.9 M) | (271.6 M) |
| IMMX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (5.4 M) | (29.8 M) | (38 M) | (53.4 M) | (50.7 M) |
| CNSP | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (7.6 M) | (11.5 M) | (20.9 M) | (35 M) | (50.7 M) | (69.6 M) | (66.1 M) |
| HEPA | (140.5 K) | (140.5 K) | (140.5 K) | (5.4 M) | (5.4 M) | (27.6 M) | (44.6 M) | (59.5 M) | (76.5 M) | (83.8 M) | (104.1 M) | (133.5 M) | (175.7 M) | (224.6 M) | (213.4 M) |
| NXTC | (24.5 M) | (24.5 M) | (24.5 M) | (24.5 M) | (24.5 M) | (24.5 M) | (24.5 M) | (24.5 M) | (47.3 M) | (81 M) | (117.6 M) | (187 M) | (261.8 M) | (324.5 M) | (308.3 M) |
| CTMX | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (78.1 M) | (117.5 M) | (176.4 M) | (219.5 M) | (315 M) | (417.2 M) | (450.1 M) | (533.7 M) | (722.9 M) | (723.4 M) | (687.3 M) |
| SPRO | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (45.4 M) | (96.8 M) | (138.5 M) | (199.4 M) | (277.7 M) | (367.5 M) | (413.9 M) | (391.1 M) | (371.5 M) |
| ASMB | (13.4 M) | (67.5 M) | (92.3 M) | (111.7 M) | (135.5 M) | (164 M) | (208.2 M) | (251 M) | (341.8 M) | (439.4 M) | (501.6 M) | (631.4 M) | (724.5 M) | (785.7 M) | (746.5 M) |
| BOLT | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (47.7 M) | (108.4 M) | (207 M) | (295.1 M) | (364.3 M) | (346.1 M) |
| CHRS | (46 M) | (46 M) | (46 M) | (99.6 M) | (186.7 M) | (410 M) | (537.3 M) | (775.5 M) | (984.8 M) | (895 M) | (762.8 M) | (1 B) | (1.3 B) | (1.6 B) | (1.5 B) |
Achieve Life Sciences and related stocks such as VectivBio Holding, Icosavax, and Apellis Pharmaceuticals Retained Earnings description
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.My Equities
My Current Equities and Potential Positions
| Achieve Life Sciences | ACHV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Washington; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.49
Additional Tools for Achieve Stock Analysis
When running Achieve Life's price analysis, check to measure Achieve Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Achieve Life is operating at the current time. Most of Achieve Life's value examination focuses on studying past and present price action to predict the probability of Achieve Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Achieve Life's price. Additionally, you may evaluate how the addition of Achieve Life to your portfolios can decrease your overall portfolio volatility.